Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Clinical trials sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, explained in plain language.
A biopharmaceutical company focused on CAR T-cell therapies for cancer, now part of Bristol-Myers Squibb.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could CAR t cells tame autoimmune brain diseases? Results expected Jul 2027 (estimated)
-
New CAR-T therapy aims to tackle Hard-to-Treat multiple myeloma
Disease control Recruiting nowThis phase 3 trial is testing a new CAR-T cell therapy called arlo-cel against standard treatments for adults with multiple myeloma that has come back or stopped responding to previous therapies. About 440 participants will receive either arlo-cel or a standard regimen. The study…
Phase 3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New CAR t therapy targets Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a new treatment called arlocabtagene autoleucel (BMS-986393) for adults with multiple myeloma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The study aims to see if this tr…
Phase 2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Engineered immune cells take on brain cancer in pioneering trial
Disease control Recruiting nowThis study is testing a new type of immunotherapy called liso-cel (Breyanzi) as the first treatment for primary central nervous system lymphoma (PCNSL), a rare brain cancer. The trial is for 65 adults who cannot have a stem cell transplant. Liso-cel is made from the patient's own…
Phase 2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New combo therapy aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage study is testing a new cell therapy (arlocabtagene autoleucel) combined with other drugs in people with multiple myeloma that has come back or stopped responding to treatment. The main goal is to find safe doses and check for side effects. About 147 adults will t…
Phase 1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Donor immune cells aim to tame autoimmune attacks
Disease control Recruiting nowThis early-stage study tests a new treatment made from healthy donor immune cells (CAR T cells) for people with severe autoimmune diseases like lupus that haven't responded to standard therapies. The goal is to see if these cells can safely target and calm the overactive immune s…
Phase 1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New Dual-Targeting CAR t therapy takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial tests a new treatment called BMS-986453 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two proteins on cancer cells, to attack the disease. The s…
Phase 1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC